CEO Yehiel Tal highlighted advancements in CollPlant's proprietary photocurable dermal filler, emphasizing its potential as a game-changer in the $6.3 billion market for aesthetic medicine.
REHOVOT, Israel, May 28, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback